UROGEN PHARMA LTD (URGN) Stock Overview
USA - NASDAQ:URGN - IL0011407140 - Common Stock
URGN Key Statistics, Chart & Performance
The current stock price of URGN is 18.17 USD. In the past month the price decreased by -6.42%. In the past year, price increased by 43.22%.
URGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.51 | 383.63B | ||
| AMGN | AMGEN INC | 12.56 | 147.44B | ||
| GILD | GILEAD SCIENCES INC | 14.55 | 139.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.26 | 101.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.55 | 60.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.39B | ||
| ARGX | ARGENX SE - ADR | 81.37 | 46.16B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.79 | 39.38B | ||
| INSM | INSMED INC | N/A | 30.18B | ||
| NTRA | NATERA INC | N/A | 23.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.36B | ||
| BIIB | BIOGEN INC | 8.96 | 21.03B |
Related stock screener links
About URGN
Company Profile
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Company Info
UROGEN PHARMA LTD
9 Ha'ta'asiya St
Ra'anana 08540 IL
CEO: Elizabeth Barrett
Employees: 235
Phone: 97297707601
UROGEN PHARMA LTD / URGN FAQ
What is the stock price of UROGEN PHARMA LTD today?
The current stock price of URGN is 18.17 USD. The price decreased by -3.3% in the last trading session.
What is the ticker symbol for UROGEN PHARMA LTD stock?
The exchange symbol of UROGEN PHARMA LTD is URGN and it is listed on the Nasdaq exchange.
On which exchange is URGN stock listed?
URGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for UROGEN PHARMA LTD stock?
14 analysts have analysed URGN and the average price target is 34.42 USD. This implies a price increase of 89.46% is expected in the next year compared to the current price of 18.17. Check the UROGEN PHARMA LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is UROGEN PHARMA LTD worth?
UROGEN PHARMA LTD (URGN) has a market capitalization of 840.54M USD. This makes URGN a Small Cap stock.
How many employees does UROGEN PHARMA LTD have?
UROGEN PHARMA LTD (URGN) currently has 235 employees.
What are the support and resistance levels for UROGEN PHARMA LTD (URGN) stock?
UROGEN PHARMA LTD (URGN) has a support level at 18.78 and a resistance level at 19.32. Check the full technical report for a detailed analysis of URGN support and resistance levels.
Is UROGEN PHARMA LTD (URGN) expected to grow?
The Revenue of UROGEN PHARMA LTD (URGN) is expected to grow by 35.99% in the next year. Check the estimates tab for more information on the URGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy UROGEN PHARMA LTD (URGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of URGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of URGN, evaluating the profitability, health, valuation and growth aspects
- UROGEN PHARMA LTD (URGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- UROGEN PHARMA LTD (URGN) Sales and EPS estimates to see what analysts future expectations are.
- UROGEN PHARMA LTD (URGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- UROGEN PHARMA LTD (URGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- UROGEN PHARMA LTD (URGN) Stock Chart to make your own analysis
- UROGEN PHARMA LTD (URGN) Latest news and press-releases to stay up to date.
Does UROGEN PHARMA LTD (URGN) stock pay dividends?
URGN does not pay a dividend.
When does UROGEN PHARMA LTD (URGN) report earnings?
UROGEN PHARMA LTD (URGN) will report earnings on 2025-11-04, before the market open.
What is the Price/Earnings (PE) ratio of UROGEN PHARMA LTD (URGN)?
UROGEN PHARMA LTD (URGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.32).
What is the Short Interest ratio of UROGEN PHARMA LTD (URGN) stock?
The outstanding short interest for UROGEN PHARMA LTD (URGN) is 16.31% of its float. Check the ownership tab for more information on the URGN short interest.
URGN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to URGN. When comparing the yearly performance of all stocks, URGN is one of the better performing stocks in the market, outperforming 91.07% of all stocks.
URGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to URGN. Both the profitability and financial health of URGN have multiple concerns.
URGN Financial Highlights
Over the last trailing twelve months URGN reported a non-GAAP Earnings per Share(EPS) of -3.32. The EPS decreased by -1.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.25% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
URGN Forecast & Estimates
14 analysts have analysed URGN and the average price target is 34.42 USD. This implies a price increase of 89.46% is expected in the next year compared to the current price of 18.17.
For the next year, analysts expect an EPS growth of 10.72% and a revenue growth 35.99% for URGN